JP2016526373A - 非コード免疫調節性共有結合閉鎖dna構築物 - Google Patents
非コード免疫調節性共有結合閉鎖dna構築物 Download PDFInfo
- Publication number
- JP2016526373A JP2016526373A JP2015563141A JP2015563141A JP2016526373A JP 2016526373 A JP2016526373 A JP 2016526373A JP 2015563141 A JP2015563141 A JP 2015563141A JP 2015563141 A JP2015563141 A JP 2015563141A JP 2016526373 A JP2016526373 A JP 2016526373A
- Authority
- JP
- Japan
- Prior art keywords
- dna
- dna construct
- construct
- cells
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Abstract
Description
5’−AGGTGGTAAC CCCTAGGGGT TACCACCTTC ATCGTCGTTT TGTCGTTTTG TCGTTCTT−3’
部分的一本鎖ダンベル型共有結合閉鎖DNA構築物の製造を記載している、欧州特許第1196178B1号明細書を参照する。本発明の構築物はこれに従って作製する。
Claims (13)
- 部分的にハイブリッド形成する配列番号1のDNA配列を2つ含んでなる、部分的に一本鎖のダンベル型をした、共有結合により閉じたDNA残基鎖からなる、免疫調節のためのDNA構築物。
- 一本鎖ループが、3つのCGモチーフを含む、請求項1に記載の構築物。
- 各CGモチーフの両側に、デオキシチミジンが隣接する、請求項1または2に記載の構築物。
- 一本鎖ループが、少なくとも50%のピリミジン含量を有する、請求項1から3のいずれか一項に記載の構築物。
- ピリミジンがデオキシチミジンである、請求項4に記載の構築物。
- 少なくとも1つヌクレオチドが、カルボキシル、アミン、アミド、アルジミン、ケタール、アセタール、エステル、エーテル、ジスルフィド、チオールおよびアルデヒド基を含む群から選択される官能基で修飾されている、請求項1から5のいずれか一項に記載の構築物。
- 修飾ヌクレオチドが、ペプチド、タンパク質、炭水化物、抗体、脂質、ミセル、ベシクル、合成分子、ポリマー、マイクロプロジェクタイル、金属粒子、ナノ粒子を含む群から選択される化合物、または固相に連結している、請求項5に記載の構築物。
- 請求項1から7のいずれか一項に記載のDNA構築物を含む医薬組成物、または請求項1から7のいずれか一項に記載のDNA構築物を含む医薬組成物。
- 化学療法剤をさらに含む、請求項8に記載の医薬組成物。
- 請求項1から7のいずれか一項に記載のDNA構築物を含むワクチン。
- 前記DNA構築物が、アジュバントとして含まれる、請求項10に記載のワクチン。
- がんまたは自己免疫疾患の治療のための、請求項1から7のいずれか一項に記載のDNA構築物、請求項8もしくは9に記載の医薬組成物、または請求項10もしくは11に記載のワクチンの使用。
- 免疫系の調節のための、請求項1から7のいずれか一項に記載のDNA構築物、請求項8もしくは9に記載の医薬組成物、または請求項10もしくは11に記載のワクチンの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1402847.6A GB2523187A (en) | 2014-02-18 | 2014-02-18 | Covalently closed non-coding immunomodulatory DNA construct |
GB1402847.6 | 2014-02-18 | ||
PCT/EP2015/053396 WO2015124614A1 (en) | 2014-02-18 | 2015-02-18 | Covalently closed non-coding immunomodulatory dna construct |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016526373A true JP2016526373A (ja) | 2016-09-05 |
JP6067893B2 JP6067893B2 (ja) | 2017-01-25 |
Family
ID=50440342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015563141A Expired - Fee Related JP6067893B2 (ja) | 2014-02-18 | 2015-02-18 | 非コード免疫調節性共有結合閉鎖dna構築物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US10280424B2 (ja) |
EP (1) | EP2999787B1 (ja) |
JP (1) | JP6067893B2 (ja) |
KR (1) | KR101831713B1 (ja) |
CN (1) | CN105264074A (ja) |
AU (1) | AU2015220911B2 (ja) |
BR (1) | BR112015025748A2 (ja) |
CA (1) | CA2908522A1 (ja) |
DK (1) | DK2999787T3 (ja) |
ES (1) | ES2634002T3 (ja) |
GB (1) | GB2523187A (ja) |
HK (1) | HK1216758A1 (ja) |
MX (1) | MX2015014190A (ja) |
RU (1) | RU2668387C2 (ja) |
SG (1) | SG11201508108YA (ja) |
WO (1) | WO2015124614A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6697384B2 (ja) | 2013-07-25 | 2020-05-20 | イグジキュア, インコーポレーテッドExicure, Inc. | 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物 |
WO2015023797A1 (en) | 2013-08-13 | 2015-02-19 | Northwestern University | Lipophilic nanoparticles for drug delivery |
GB2523187A (en) * | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
TR201908550T4 (tr) | 2014-06-04 | 2019-07-22 | Exicure Inc | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. |
US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
GB2542425A (en) * | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
JP2020531555A (ja) | 2017-08-31 | 2020-11-05 | モロゲン・アーゲー | 腫瘍微小環境のモジュレーションのためのtlr−9アゴニスト |
CA3164390A1 (en) * | 2020-01-31 | 2021-08-05 | Tyris Therapeutics, S.L. | Closed linear dna with modified nucleotides |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001007055A1 (de) * | 1999-07-27 | 2001-02-01 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Kovalent geschlossenes nukleinsäuremolekül zur immunstimulation |
WO2006015560A1 (de) * | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2490449A1 (en) * | 2002-06-25 | 2003-12-31 | City Of Hope | Adjuvant-free peptide vaccine |
EP1605973B1 (en) * | 2003-03-26 | 2012-09-26 | Cytos Biotechnology AG | Packaging of immunostimulatory oligonucleotides into virus-like particles: methods of preparation and uses |
CN101454451A (zh) | 2003-10-30 | 2009-06-10 | 科勒制药有限公司 | 具有增强免疫刺激能力的c类寡核苷酸类似物 |
RU2354694C2 (ru) * | 2003-12-30 | 2009-05-10 | Мологен Аг | Аллогенное противоопухолевое терапевтическое средство |
DK1716234T3 (da) | 2004-02-20 | 2014-01-20 | Mologen Ag | Substitueret, ikke-kodende nukleinsyremolekyle til terapeutisk og profylaktisk immunstimulering i mennesker og højerestående dyr |
CN101490257A (zh) * | 2006-05-11 | 2009-07-22 | 莫洛根股份公司 | 用于免疫刺激的多聚体 |
WO2010039137A1 (en) | 2008-10-02 | 2010-04-08 | Idera Pharmaceuticals, Inc. | Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response |
EP2246433A1 (de) | 2009-04-30 | 2010-11-03 | Mologen AG | Concatemere zur Immunmodulation |
GB2523187A (en) * | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
-
2014
- 2014-02-18 GB GB1402847.6A patent/GB2523187A/en not_active Withdrawn
-
2015
- 2015-02-18 AU AU2015220911A patent/AU2015220911B2/en not_active Ceased
- 2015-02-18 ES ES15706416.3T patent/ES2634002T3/es active Active
- 2015-02-18 RU RU2015140720A patent/RU2668387C2/ru not_active IP Right Cessation
- 2015-02-18 KR KR1020157028152A patent/KR101831713B1/ko active IP Right Grant
- 2015-02-18 DK DK15706416.3T patent/DK2999787T3/en active
- 2015-02-18 EP EP15706416.3A patent/EP2999787B1/en not_active Not-in-force
- 2015-02-18 CA CA2908522A patent/CA2908522A1/en not_active Abandoned
- 2015-02-18 MX MX2015014190A patent/MX2015014190A/es unknown
- 2015-02-18 US US14/899,601 patent/US10280424B2/en active Active
- 2015-02-18 SG SG11201508108YA patent/SG11201508108YA/en unknown
- 2015-02-18 BR BR112015025748A patent/BR112015025748A2/pt not_active IP Right Cessation
- 2015-02-18 JP JP2015563141A patent/JP6067893B2/ja not_active Expired - Fee Related
- 2015-02-18 CN CN201580000576.0A patent/CN105264074A/zh active Pending
- 2015-02-18 WO PCT/EP2015/053396 patent/WO2015124614A1/en active Application Filing
-
2016
- 2016-04-20 HK HK16104520.3A patent/HK1216758A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001007055A1 (de) * | 1999-07-27 | 2001-02-01 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Kovalent geschlossenes nukleinsäuremolekül zur immunstimulation |
WO2006015560A1 (de) * | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen |
Also Published As
Publication number | Publication date |
---|---|
US10280424B2 (en) | 2019-05-07 |
ES2634002T3 (es) | 2017-09-26 |
HK1216758A1 (zh) | 2016-12-02 |
RU2668387C2 (ru) | 2018-09-28 |
GB201402847D0 (en) | 2014-04-02 |
KR101831713B1 (ko) | 2018-02-23 |
EP2999787A1 (en) | 2016-03-30 |
RU2015140720A (ru) | 2017-03-29 |
CN105264074A (zh) | 2016-01-20 |
AU2015220911B2 (en) | 2017-02-02 |
SG11201508108YA (en) | 2015-10-29 |
JP6067893B2 (ja) | 2017-01-25 |
MX2015014190A (es) | 2015-12-11 |
BR112015025748A2 (pt) | 2017-10-10 |
CA2908522A1 (en) | 2015-08-27 |
EP2999787B1 (en) | 2017-04-19 |
WO2015124614A1 (en) | 2015-08-27 |
GB2523187A (en) | 2015-08-19 |
KR20150130425A (ko) | 2015-11-23 |
DK2999787T3 (en) | 2017-08-07 |
US20160348114A1 (en) | 2016-12-01 |
AU2015220911A1 (en) | 2015-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6067893B2 (ja) | 非コード免疫調節性共有結合閉鎖dna構築物 | |
US20210340543A1 (en) | Non-coding immunomodulatory dna construct | |
JP7436535B2 (ja) | 免疫刺激オリゴヌクレオチドを含む組合せ | |
Krieg et al. | Mechanisms and therapeutic applications of immune stimulatory CpG DNA | |
JP2008000001A (ja) | 免疫刺激オリゴヌクレオチドおよびその医薬用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20160712 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160802 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160905 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161221 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6067893 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |